2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Leukemia, Myeloid, Acute
5
Lymphoma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Myelodysplastic Syndromes
3
Multiple Myeloma
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Leukemia
3
Waldenstrom Macroglobulinemia
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Hodgkin Disease
2
Spondylolisthesis
1
Spinal Stenosis
1
Spinal Cord Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Intervertebral Disc Displacement
1
Intervertebral Disc Degeneration
1
Hemoglobinuria, Paroxysmal
1
Interventions
Docetaxel
292
Prednisone
241
enzalutamide
195
Leuprolide
185
Radiotherapy
179
Abiraterone Acetate
170
Magnetic Resonance Spectroscopy
163
bicalutamide
141
Goserelin
138
Androgen Antagonists
121
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
108
Radiosurgery
108
apalutamide
93
abiraterone
83
gallium 68 PSMA-11
81
Specimen Handling
73
darolutamide
67
Surveys and Questionnaires
64
Gonadotropin-Releasing Hormone
63
Triptorelin Pamoate
58
Radiation
57
Biopsy
57
Brachytherapy
54
cabazitaxel
53
Standard of Care
51
Radiotherapy, Intensity-Modulated
51
Zoledronic Acid
50
pembrolizumab
49
luprolide acetate gel depot
49
Flutamide
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Transplantation, Homologous
×
Clear all
NCT06940271
2025-11-10
RAP
Mayo Clinic
Phase NA
Recruiting
25 enrolled